ESMO 2023 | ctDNA in lung cancer: implications and applications

James R. Black, MD, UCL, London, discusses the multifaceted implications of circulating tumor DNA (ctDNA). Beyond its role in TNM staging and predicting prognosis, ctDNA proves valuable in minimal residual disease assessment during follow-up, anticipating relapse before routine clinical surveillance. The the TRACERx study (NCT01888601) emphasizes the preoperative significance of ctDNA, using samples collected during surgery to stratify patients for tailored treatment. Dr Black highlights the potential utility in high-risk stage one tumors, aiding in predicting relapse and guiding treatment escalation or deescalation. Notably, 100% of ctDNA-negative patients with stage one lung cancer survived after five years, suggesting potential for less intensive surveillance. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP), protected by copyright laws and treaties around the world. All rights are reserved.